Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

NCT01963611 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

255

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated based on sponsor discretion.

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Plovamer acetate 0.5 milligram (mg)
DRUG: Copaxone 20 mg
DRUG: Plovamer acetate 3 mg
DRUG: Plovamer acetate 10 mg
DRUG: Plovamer acetate 20 mg

Sponsor

EMD Serono